Mather Group’s Haemonetics HAE Stock Holding History

Mather Group’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-46	Closed	-$3.93K	–	1914
2024 Q2	$3.93K	Buy	+46	New	+$4.05K	﹤0.01%	1694

Other funds holding HAE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

Mather Group's HAE Position: Q3 2024 in Review

Mather Group sold out of Haemonetics (HAE) in Q3 2024, closing a stake of 46 shares — an estimated $3.93K sold.

Mather Group first reported a position in HAE in Q2 2024 and held it in 1 quarter. The position peaked at $3.93K in Q2 2024. 306 funds tracked by Wall St. Rank hold HAE as of Q3 2024.

Mather Group reported no remaining Haemonetics position as of Q3 2024 after selling out during the quarter.
Mather Group sold 46 Haemonetics shares in Q3 2024, an estimated $3.93K.
Mather Group first reported a position in Haemonetics in Q2 2024 and held it in 1 quarter.
Mather Group's Haemonetics position peaked at $3.93K in Q2 2024.
306 funds tracked by Wall St. Rank held Haemonetics as of Q3 2024.

Based on Mather Group's 13F filing for Q3 2024, filed 7 Oct 2024.